Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 5/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | PLAT | P00750 | 2/20 | 0.37 |
| ▸ | F7 | P08709 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960900 | 0.75 | BDKRB1 (0.42) | MYCWDR5LTB4R2AGTR1AGTR2 | |
| SCHEMBL3977067 | 0.73 | LTB4R2 (0.43) | MYCWDR5LTB4R2AGTR1AGTR2 | |
| SCHEMBL8419109 | 0.71 | FFAR1 (0.39) | LTB4R2AGTR1AGTR2FFAR1AKR1B1 | |
| SCHEMBL6064774 | 0.68 | LTB4R2 (0.46) | HDAC1HDAC6LTB4R2 | |
| SCHEMBL4680424 | 0.67 | NPC1 (0.49) | LTB4R2 | |
| SCHEMBL9429910 | 0.66 | LTB4R2 (0.53) | HDAC1HDAC6LTB4R2AGTR1FFAR1 | |
| SCHEMBL20183666 | 0.65 | LTB4R2 (0.72) | LTB4R2AGTR1 | |
| SCHEMBL8472095 | 0.65 | FFAR1 (0.41) | MYCWDR5LTB4R2AGTR1AGTR2 | |
| SCHEMBL6606543 | 0.65 | HRH4 (0.54) | MYCWDR5AGTR1ACHEPPARG | |
| SCHEMBL9429769 | 0.64 | LTB4R2 (0.49) | HDAC1HDAC6LTB4R2AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | disclosed |
| US-6844443-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2005-01-18 | — | — | US | disclosed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | disclosed |
| US-6608210-B2 | Such as 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-((2'-(1H-tetrazol-t-yl)biphenyl-4-yl)methyl) benzimidazol-7-carboxylate; exhibits antihypertensive activity and strong angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-0720982-B1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | disclosed |
| US-6355808-B2 | ANGAGONIZING ANGIOTENSIN II | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | MYC 792/4885WDR5 3498/4885F2 851/4885 |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | MYC 824/4885WDR5 2920/4885F2 1741/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | MYC 863/4885WDR5 3826/4885F2 1934/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | MYC 897/4885WDR5 3856/4885F2 2016/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | MYC 956/4885WDR5 4274/4885F2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.